Publications by authors named "P Carluccio"

Article Synopsis
  • Allogeneic stem cell transplantation (allo-SCT) offers curative potential for multiple myeloma patients but is effective in only a minority, with some patients experiencing long-term survival after relapse thanks to a combination of antimyeloma drugs and donor T cells.
  • A study evaluating 242 multiple myeloma patients who underwent allo-SCT revealed a median overall survival of 39.4 months and highlighted factors like older age and previous therapies that predict shorter survival outcomes.
  • Among 118 relapsed patients, various treatments were employed, with a significant portion receiving multiple lines of salvage therapy, including chemotherapy and immunomodulating agents, demonstrating a diverse treatment approach post-relapse.
View Article and Find Full Text PDF
Article Synopsis
  • * After a median follow-up of 10 years, 117 patients were assessed, with half receiving ATO and half receiving chemotherapy.
  • * Results showed that ATO treatment was associated with significantly better cognitive function and lower fatigue, indicating sustained HRQoL benefits compared to chemotherapy over the long term.
View Article and Find Full Text PDF

Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), is a rare but potentially fatal complication following allogenic hematopoietic cell transplantation (allo-HCT). Timely identification of SOS/VOD to allow for prompt treatment is critical, but identifying a VOD-predictive biomarker remains challenging. Given the pivotal role of endothelial dysfunction in SOS/VOD pathophysiology, the CECinVOD study prospectively evaluated levels of circulating endothelial cells (CECs) in patients undergoing allo-HCT with a myeloablative conditioning (MAC) regimen to investigate the potential of CEC level in predicting and diagnosing SOS/VOD.

View Article and Find Full Text PDF

gene mutations, detected in 20-25% of acute myeloid leukemia (AML) patients, are typically heterozygous. Biallelic variants are uncommon, affecting ~3% of cases and identifying a worse prognosis. Indeed, two concomitant mutations were recently associated with shorter event-free survival and overall survival in AML.

View Article and Find Full Text PDF